Vertex Pharmaceuticals Incorporated
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1989-01-01
- Employees
- 5.4K
- Market Cap
- $123.9B
- Website
- http://www.vrtx.com
An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-12-19
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 34
- Registration Number
- NCT02015507
Roll-Over Study of Ivacaftor in Cystic Fibrosis Pediatric Subjects With a CF Transmembrane Conductance Regulator Gene (CFTR) Gating Mutation
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 33
- Registration Number
- NCT01946412
A Phase 3 Rollover Study of Lumacaftor in Combination With Ivacaftor in Subjects 12 Years and Older With Cystic Fibrosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2017-05-12
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 1164
- Registration Number
- NCT01931839
Phase 1, QT/QTC Interval Study in Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-29
- Last Posted Date
- 2014-08-11
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 200
- Registration Number
- NCT01910415
A Phase 1 Study to Investigate the Food Effect of Lumacaftor in Combination With Ivacaftor
- First Posted Date
- 2013-07-15
- Last Posted Date
- 2014-04-03
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT01899105
Study of Lumacaftor in Combination With Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2017-06-20
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 62
- Registration Number
- NCT01897233
Study of Lumacaftor in Combination With Ivacaftor in Subjects With Moderate Hepatic Impairment and Healthy Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-27
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 23
- Registration Number
- NCT01888393
Phase 1 PK Interaction Study Between VX-509 and Prednisone or Methylprednisolone in Healthy Male Subjects
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-06-25
- Last Posted Date
- 2013-08-14
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 28
- Registration Number
- NCT01886209
- Locations
- 🇺🇸
Vertex Investigational Site, Lenexa, Kansas, United States
An Ocular Safety Study of Ivacaftor-Treated Pediatric Patients 11 Years of Age or Younger With Cystic Fibrosis
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-05-27
- Last Posted Date
- 2016-08-23
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 95
- Registration Number
- NCT01863238
A Phase 2 Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-135 and Daclatasvir in Subjects With Genotype 1 Chronic Hepatitis C Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-04-29
- Last Posted Date
- 2015-12-29
- Lead Sponsor
- Vertex Pharmaceuticals Incorporated
- Target Recruit Count
- 23
- Registration Number
- NCT01842451
- Locations
- 🇳🇿
New Zealand, Christchurch, New Zealand
© Copyright 2024. All Rights Reserved by MedPath